This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting
Phase 3

Rexlemestrocel-L & HA

Sponsor:

Mesoblast, Ltd.

Code:

NCT06325566

Conditions

Degenerative Disc Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rexlemestrocel-L + HA mixture

Saline

Study Details

Brief summary:

The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.

Conditions

Degenerative Disc Disease

Study ID

NCT06325566

Start date

Jul 3, 2024

Status verified date

Jun, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

Jul, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants with moderate to severe low back pain for a duration of at least six months who have failed at least 3 months of conservative care.
  • Participants who have moderate radiographic degeneration of an intervertebral disc from L1 to S1, with a single disc suspected of causing chronic lower back pain (CLBP).

Exclusion Criteria:

  • Participants who have been a recipient of prior allogeneic stem cell/progenitor cell therapy for any indication or autologous stem cell/progenitor cell therapy or other biological intervention to repair the index intervertebral disc.
  • Participants with low back pain duration of less than 6 months or greater than 60 months.
  • Participants who have not received at least 3 months of conservative treatment for back pain without adequate pain relief.
  • Participants taking systemic immunosuppressants.
  • Participants with osteoporosis.
  • Participants with alcohol or substance abuse problems.
  • Participants with severe depression or anxiety.
  • Participants with cauda equina syndrome; fibromyalgia, symptomatic central vertebral canal stenosis, lumbar spondylitis or other undifferentiated spondyloarthropathy affecting the index disc.
  • Participants having undergone a surgical procedure affecting the structure/biomechanics of the disc (e.g., discectomy, intradiscal electrothermal therapy, intradiscal radiofrequency, artificial disc replacement, interbody fusion, laminectomy, etc.) at the index or adjacent levels.
  • Participants who have received any lumbar intradiscal injection into the index disc or adjacent discs within three months prior to the start of screening, other than injection of contrast medium for discography.
  • Participants who received an epidural steroid injection within 6 weeks prior to informed consent.
  • Participants with evidence of neurologic deficit on any component of the lumbar neurological exam at baseline.
  • Participants with sacroiliac (SI) joint pain, as determined by a targeted physical exam, or SI joint injection.
  • Participants with facet joint pain, as determined by a medial branch block.
  • Participants with more than a single painful level.
  • Participants with a full thickness annular tear observed on magnetic resonance imaging (MRI) or discography.
  • Participants with low back pain that is less than moderate in severity.
  • Participants with extreme low back pain.
  • Participants who lack moderate to extreme functional limitations/disability.

Note: Other exclusion criteria may apply.

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Rexlemestrocel-L + HA

Participants will receive rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0.

sham comparator: Control Group

Participants will receive saline solution as a sham procedure to simulate the active treatment injection on Day 0.

Interventions

Rexlemestrocel-L + HA mixture

Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.

Saline

Saline solution injection adjacent to the index disc.

Primary outcome measure

  • Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) Score [ Time Frame: Baseline and Month 12 ]
  • Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to Month 24 ]

Central Contacts and Locations

More Information

Sponsor

Mesoblast, Ltd.

Last update posted

Jun 17, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-21. This information was provided to ClinicalTrials.gov by Mesoblast, Ltd. on 2026-06-17.